Bupropion (Zyban) is a medication licensed in the UK for smoking cessation, working by increasing norepinephrine and dopamine in the brain. For patients with fatty liver disease or those concerned about liver health, understanding how bupropion interacts with hepatic conditions is essential. Whilst bupropion is metabolised in the liver and requires dose adjustment in moderate hepatic impairment, current evidence does not suggest it causes or worsens fatty liver disease. This article examines the relationship between bupropion and fatty liver disease, including monitoring requirements, precautions, and alternative treatment options for patients with liver concerns.
Summary: Bupropion is not known to cause or worsen fatty liver disease, but requires dose reduction in moderate hepatic impairment and is contraindicated in severe cirrhosis.
- Bupropion is a norepinephrine-dopamine reuptake inhibitor licensed in the UK for smoking cessation, metabolised primarily by the liver enzyme CYP2B6.
- Current evidence does not identify bupropion as causing hepatic steatosis, though rare cases of idiosyncratic liver injury have been reported.
- In moderate hepatic impairment, the maximum dose is 150 mg once daily; bupropion should be avoided in severe hepatic cirrhosis.
- Baseline liver function tests are recommended for patients with known or suspected liver disease before starting bupropion.
- Patients should report symptoms of liver dysfunction such as jaundice, dark urine, persistent nausea, or unexplained fatigue promptly to their healthcare provider.
- Alternative smoking cessation options include nicotine replacement therapy, varenicline, and behavioural support programmes, which are generally safe in liver disease.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is Bupropion and How Does It Work?
Bupropion (marketed as Zyban in the UK) is a medication licensed for smoking cessation in adults. It is not licensed in the UK for the treatment of depression, although it may occasionally be prescribed for this purpose by specialists as an unlicensed indication. Unlike many other antidepressants, bupropion does not belong to the selective serotonin reuptake inhibitor (SSRI) class. Instead, it functions as a norepinephrine-dopamine reuptake inhibitor (NDRI), which means it works by increasing the availability of norepinephrine and dopamine in the brain.
The mechanism of action involves blocking the reuptake of these neurotransmitters at neuronal synapses, thereby enhancing their activity in brain circuits associated with mood regulation and reward pathways. In smoking cessation, bupropion is thought to reduce nicotine cravings and withdrawal symptoms through its effects on dopaminergic pathways.
Key characteristics of bupropion (Zyban) in the UK include:
-
Available as prolonged-release 150 mg tablets
-
Licensed dosing regimen: 150 mg once daily for 6 days, then 150 mg twice daily (at least 8 hours apart); maximum 300 mg per day
-
Treatment typically lasts 7–9 weeks; quit date set for second week of treatment
-
Lower risk of sexual dysfunction and weight gain compared to SSRIs (when used unlicensed for depression)
-
Contraindicated in patients with seizure disorders, current or past eating disorders (bulimia or anorexia nervosa), severe hepatic cirrhosis, and those taking monoamine oxidase inhibitors (MAOIs) within the previous 14 days
-
Caution required in patients undergoing abrupt withdrawal from alcohol or benzodiazepines
Bupropion is metabolised primarily in the liver by the cytochrome P450 enzyme system, particularly CYP2B6, producing active metabolites. This hepatic metabolism is relevant when considering the drug's use in patients with liver conditions. Important interactions include drugs that lower the seizure threshold (such as tramadol, antipsychotics, theophylline, systemic corticosteroids, and high-dose quinolones) and medications that inhibit or induce CYP2B6. Blood pressure should be monitored before starting treatment and during therapy, as bupropion can increase blood pressure; the risk of hypertension is higher when bupropion is combined with nicotine replacement patches. The Medicines and Healthcare products Regulatory Agency (MHRA) provides guidance on bupropion's use, and prescribers must consider individual patient factors, including liver function and seizure risk, when initiating treatment.
Understanding Fatty Liver Disease and Its Causes
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. This condition exists in two main forms: non-alcoholic fatty liver disease (NAFLD), also increasingly referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-related fatty liver disease (ARLD). NAFLD is increasingly common in the UK, affecting a substantial proportion of the general population, whilst ARLD develops in individuals with significant alcohol consumption.
Non-alcoholic fatty liver disease encompasses a spectrum of conditions, from simple steatosis (fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential liver cell damage. If left unmanaged, NASH can progress to fibrosis, cirrhosis, and in some cases, hepatocellular carcinoma. The condition is often asymptomatic in early stages, making incidental detection through blood tests or imaging studies common. It is important to note that liver blood tests (liver function tests or LFTs) can be entirely normal in people with NAFLD; diagnosis and risk assessment typically require imaging (such as ultrasound) and non-invasive fibrosis risk scores.
Major risk factors for NAFLD include:
-
Obesity and central adiposity
-
Type 2 diabetes mellitus
-
Metabolic syndrome (hypertension, dyslipidaemia, insulin resistance)
-
Sedentary lifestyle and poor dietary habits
The pathophysiology of NAFLD involves complex interactions between insulin resistance, lipid metabolism, oxidative stress, and inflammatory pathways. Excess dietary calories, particularly from refined carbohydrates and saturated fats, contribute to hepatic fat accumulation. The liver's capacity to process and export fat becomes overwhelmed, leading to steatosis.
Regarding bupropion specifically, bupropion is not known to cause or worsen fatty liver disease. Current evidence does not identify bupropion as a medication that induces hepatic steatosis. However, rare cases of idiosyncratic liver injury, including hepatitis and elevated liver enzymes, have been reported with bupropion and are listed in the Summary of Product Characteristics (SmPC). Because bupropion undergoes hepatic metabolism, caution is advised in patients with pre-existing liver impairment, and dose adjustments are necessary according to the SmPC and British National Formulary (BNF). In patients with moderate hepatic impairment, the maximum dose is 150 mg once daily; bupropion should be avoided in severe hepatic cirrhosis.
Monitoring and Precautions When Taking Bupropion
When prescribing bupropion, healthcare professionals should conduct a thorough assessment, including evaluation of seizure risk, blood pressure, liver function, and potential drug interactions. Baseline blood pressure measurement is recommended before starting treatment, with periodic monitoring during therapy, particularly in patients using concurrent nicotine replacement patches, as the combination increases the risk of hypertension.
For patients with known or suspected liver disease, or those with risk factors for hepatic impairment, baseline liver function tests (LFTs)—including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin—provide important information about hepatic health. Routine monitoring of LFTs is not required for all patients but should be considered in those with liver disease or if symptoms suggestive of liver dysfunction develop.
For patients with moderate hepatic impairment, the BNF and SmPC recommend dose reduction to a maximum of 150 mg once daily. In severe hepatic cirrhosis, bupropion is contraindicated due to the risk of drug accumulation and potential adverse effects. The reduced clearance of bupropion and its active metabolites in liver disease increases the risk of seizures, which is already a dose-dependent concern with this medication. To minimise seizure risk, the maximum single dose is 150 mg, and doses should be spaced at least 8 hours apart.
Important monitoring considerations include:
-
Blood pressure measurement before starting and periodically during treatment
-
Baseline liver function tests in patients with known or suspected liver disease or risk factors
-
Follow-up LFTs if symptoms of liver dysfunction develop
-
Assessment for signs of liver dysfunction (jaundice, dark urine, abdominal pain, unexplained nausea or fatigue)
-
Regular review of concomitant medications, particularly those that lower seizure threshold (tramadol, antipsychotics, theophylline, systemic corticosteroids, high-dose quinolones) or affect CYP2B6 metabolism
Common side effects of bupropion that patients should be aware of:
-
Insomnia and sleep disturbances (often improved by avoiding evening doses and spacing doses appropriately)
-
Dry mouth and headache
-
Nausea and gastrointestinal upset
-
Tremor and agitation
-
Increased blood pressure in some individuals
Patients should be counselled about the importance of reporting any new symptoms, particularly those suggestive of liver problems such as persistent nausea, unusual fatigue, yellowing of the skin or eyes, or dark-coloured urine. Whilst serious hepatotoxicity with bupropion is rare, vigilance ensures early detection of any adverse hepatic reactions. Healthcare professionals should also review alcohol consumption, as excessive alcohol use both increases seizure risk with bupropion and contributes to liver disease progression. Patients and healthcare professionals are encouraged to report suspected adverse effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.
Alternative Treatments and When to Seek Medical Advice
For patients seeking smoking cessation support who have concerns about liver health or for whom bupropion is unsuitable, several alternative treatment options exist. NICE guidance recommends a combination of behavioural support and pharmacotherapy for the best chance of successfully stopping smoking. The choice of therapy should be individualised based on the patient's specific condition, liver function status, comorbidities, and treatment goals.
For smoking cessation, alternatives to bupropion include:
-
Nicotine replacement therapy (NRT) in various forms (patches, gum, lozenges, inhalators, nasal spray, mouth spray)—generally safe in liver disease
-
Varenicline—requires dose adjustment in severe renal impairment but not specifically contraindicated in liver disease; caution advised
-
Behavioural support programmes offered through NHS Stop Smoking Services, which provide evidence-based counselling and support
-
Combination approaches using NRT plus behavioural support, which are often most effective
For patients in whom bupropion has been considered for unlicensed use in depression and who have liver concerns, alternative antidepressants may include SSRIs such as sertraline or citalopram, or mirtazapine, though dose adjustments may be needed in hepatic impairment. Psychological therapies, particularly cognitive behavioural therapy (CBT), are recommended by NICE as first-line treatments for mild to moderate depression and do not carry risks related to liver metabolism.
Management of fatty liver disease itself focuses on lifestyle modification as the cornerstone of treatment. NICE guidance (NG49) emphasises weight loss (7–10% of body weight for those who are overweight), increased physical activity (at least 150 minutes of moderate-intensity exercise weekly), dietary improvements (Mediterranean-style diet, reduced intake of free sugars and refined carbohydrates), and management of associated metabolic conditions such as diabetes, hypertension, and dyslipidaemia.
NAFLD risk stratification and monitoring (NICE NG49): In primary care, adults with suspected NAFLD should have their risk of advanced liver fibrosis assessed using the FIB-4 score or NAFLD fibrosis score. For adults under 65 years, a FIB-4 score below 1.3 suggests low risk; a score above 2.67 suggests high risk. For adults aged 65 and over, a lower threshold (FIB-4 <2.0) indicates low risk. Patients with indeterminate or high-risk scores should be offered enhanced liver fibrosis (ELF) blood test or referred to hepatology services for further assessment. Those at low risk should have lifestyle advice reinforced and repeat risk stratification every 2–3 years if risk factors persist.
Patients should seek medical advice promptly if they experience:
-
Yellowing of the skin or whites of the eyes (jaundice)
-
Persistent abdominal pain, particularly in the upper right quadrant
-
Unexplained fatigue, nausea, or loss of appetite lasting more than a few days
-
Dark urine or pale stools
-
Easy bruising or bleeding
-
Confusion or altered mental state
Urgent or emergency assessment (same day or 999) is required for:
-
Vomiting blood or passing black, tarry stools (melaena)
-
Severe confusion, drowsiness, or loss of consciousness
-
Rapidly increasing abdominal swelling or girth
Regular follow-up with a GP is essential for patients taking bupropion, particularly those with pre-existing liver conditions or risk factors for fatty liver disease. Healthcare professionals can monitor treatment response, assess for adverse effects, and adjust management plans accordingly. For patients with confirmed fatty liver disease, referral to hepatology services is appropriate if there is evidence of advanced fibrosis (based on FIB-4, ELF, or imaging), persistently elevated liver enzymes despite lifestyle modification, or diagnostic uncertainty. The multidisciplinary approach, involving GPs, smoking cessation advisers, hepatologists, and specialist nurses, ensures comprehensive care that addresses both smoking cessation or mental health needs and liver health concerns.
Frequently Asked Questions
Can I take bupropion if I have fatty liver disease?
Yes, bupropion can be taken if you have fatty liver disease, as it is not known to cause or worsen the condition. However, if you have moderate hepatic impairment, your dose will be reduced to a maximum of 150 mg once daily, and bupropion is contraindicated in severe cirrhosis due to the risk of drug accumulation and increased seizure risk.
Does bupropion damage the liver or make fatty liver worse?
Bupropion does not cause or worsen fatty liver disease based on current evidence. Whilst rare cases of idiosyncratic liver injury (hepatitis and elevated liver enzymes) have been reported, bupropion is not associated with inducing hepatic steatosis or progression of existing fatty liver disease.
What are safer alternatives to bupropion for quitting smoking if I have liver problems?
Nicotine replacement therapy (NRT) in forms such as patches, gum, or lozenges is generally safe in liver disease and does not require dose adjustment. Varenicline is another option, though caution is advised, and behavioural support programmes through NHS Stop Smoking Services provide evidence-based counselling without medication-related liver concerns.
Will my doctor need to check my liver before prescribing bupropion?
If you have known or suspected liver disease or risk factors for hepatic impairment, your doctor should perform baseline liver function tests before starting bupropion. Routine monitoring is not required for all patients, but follow-up tests are recommended if symptoms of liver dysfunction develop during treatment.
What symptoms should I watch for that might mean bupropion is affecting my liver?
You should report yellowing of the skin or eyes (jaundice), dark urine, persistent nausea, unexplained fatigue, or abdominal pain to your GP promptly. Whilst serious liver toxicity with bupropion is rare, early detection of any adverse hepatic reactions is important for your safety.
How does bupropion compare to other antidepressants for people with fatty liver?
Bupropion is not licensed for depression in the UK but may be prescribed unlicensed by specialists; it requires dose reduction in moderate hepatic impairment. Alternative antidepressants such as SSRIs (sertraline, citalopram) or mirtazapine may also need dose adjustments in liver disease, and psychological therapies like CBT are recommended as first-line treatments without liver metabolism concerns.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
